EGFR

[Cend Therapeutics, Inc. (GlobeNewswire, Inc.)] Patient dosing has begun in a Phase Ib/IIa clinical trial to evaluate the safety, tolerability and pharmacologic activity of CEND-1, an investigational drug that modifies the tumor microenvironment, in pancreatic, appendiceal and colon cancers in collaboration with the University of Kansas Cancer Center.

[Scientific Reports] Breast cancer cells preferentially metastasize to bone. To study the bone-tumor paracrine influence, a tri-cellular 3-D vascularized breast cancer tissue model was engineered which comprised MDA-MB231, TNBCs, fibroblasts, and endothelial cells.

[Cell Death Discovery] Researchers showed that gefitinib significantly induced downregulation of Sterol Regulator Element Binding (SREBP1) in therapy-sensitive cells.

[Molecular Cancer Research] Researchers identified the cell surface binding partner of Reg4 and dissected its role in colorectal cancer (CRC) and pancreatic cancer (PC) growth and stem cell survival. In vitro models of human CRC and PC were used to evaluate the results.

[Cell Death & Disease] Researchers demonstrated that kinectin1 knockdown induced epidermal growth factor receptor (EGFR) degradation in cutaneous squamous cell carcinoma cells and promoted the ubiquitin-proteasome system, and that this effect was tumor cell-specific.

[Servier (Business Wire, Inc.)] Servier announced that the primary objective of the Phase III SOLSTICE trial has not been met. SOLSTICE was designed to evaluate the superiority of LONSURF® + bevacizumab over capecitabine + bevacizumab in first line unresectable metastatic colorectal cancer.